EXASOL
24.9.2020 10:17:10 CEST | Business Wire | Press release
Exasol , the high-performance analytics database, achieved 18 top-rankings and 4 leading positions in its two peer groups in The Data Management Survey 20. In addition, 100 percent of Exasol users chose the Exasol database because of its convincing performance and would recommend it to others. The survey was conducted by BARC (Business Application Research Center), Europe’s leading analyst firms for business software based in Würzburg, Germany.
“Exasol achieved truly remarkable results in the Data Management Survey 2020 with 18 top rankings,” said Timm Grosser, Senior Analyst Data & Analytics at BARC and author of the study. “Users gave Exasol the highest possible score for two crucial criteria when it comes to data platforms: 'performance' and 'platform reliability'. In today’s world, users need reliable and fast data for their operational and analytical processes. Similarly, the stability and performance of a data platform, even under pressure and high demand, are business-critical. Exasol has ranked impressively well in all the key areas and 100 percent of users surveyed in the Data Management Survey would recommend its high-performance analytics database to others.”
In the survey, twelve products were grouped into six peer groups to make them more comparable. The Exasol database was evaluated in both the Analytical Database Products peer group and the Data Warehouse Technologies peer group using twelve KPIs determined by BARC research. In both peer groups, the Exasol database was ranked top in the following categories:
- Time to market;
- Innovation power;
- Performance;
- Platform reliability;
- Support quality;
- Breadth of supported use cases;
- Product satisfaction;
- Recommendation.
In the group of Analytical Database Products, Exasol also achieved the top positions for Price-to-value and Functionality.
Exasol was ranked as a leader—among the top 25 to 30 percent of the products in the group—in the Developer Efficiency category in both peer groups, and in the data warehouse technologies peer group in the Price-to-value and Functionality categories.
“We are proud of our top rankings in BARC’s The Data Management Survey 2020. These excellent results show the high satisfaction of our customers,” said Aaron Auld, CEO of Exasol. “The fact that we scored ten out of ten in each of the two peer groups in the categories for Recommendation, Platform Reliability and Performance proves that we not only have the most powerful database for analytical workloads, but that we are committed to ensuring that our platform enables our customers to make data-driven decisions based on the most up-to-date data every day.”
The survey also shows that 93 percent of Exasol users use the database for data warehousing and business intelligence (BI) and 69 percent for data integration. Download the report, which includes a detailed overview of Exasol’s highlight results in BARC’S The Data Management Survey 2020.
###
About The Data Management Survey
The Data Management Survey 20 was conducted by BARC from December 2019 to March 2020. Altogether, 634 respondents worldwide answered a series of questions about their data management software. The survey offers a comparison of 12 leading data management tools across 12 criteria (KPIs) including developer efficiency, recommendation, time to market and product satisfaction. For more information, go to www.bi-survey.com.“
About Exasol
The Exasol high-performance analytics database is built to run faster than any other database, delivering next-level performance, scale and ease of use. Analyze billions of rows in seconds; run high-performance analytics securely in the cloud or on-premise; deliver frictionless analytics with self-indexing that automatically tunes performance; and scale out analytics for one transparent price. To learn more, please visit: www.exasol.com
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005061/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
